MedKooCat#:205645
Name:Birinapant(TL32711)
CAS#:1260251-31-7
ChemicalFormula:C42H56F2N8O6
ExactMass:806.42909
MolecularWeight:806.94
ElementalAnalysis:C,62.51;H,6.99;F,4.71;N,13.89;O,11.90
Synonym:TL32711;TL-32711;TL32711;SMACmimetic;Birinapant
IUPAC/ChemicalName:(2S)-N-[(2S)-1-[(2R,4S)-2-[[6-fluoro-2-[6-fluoro-3-[[(2R,4S)-4-hydroxy-1-[(2S)-2-[[(2S)-2-(methylamino)propanoyl]amino]butanoyl]pyrrolidin-2-yl]methyl]-1H-indol-2-yl]-1H-indol-3-yl]methyl]-4-hydroxypyrrolidin-1-yl]-1-oxobutan-2-yl]-2-(methylamino)propanamide
InChiKey:PKWRMUKBEYJEIX-DXXQBUJASA-N
InChiCode:InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1
SMILESCode:C[C@H](NC)C(N[C@@H](CC)C(N1[C@H](CC2=C(C(N3)=C(C[C@H]4N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C4)C5=C3C=C(F)C=C5)NC6=C2C=CC(F)=C6)C[C@H](O)C1)=O)=O
TechnicalData
AdditionalInformation
InPhase1clinicalstudiesasasingleagentandincombinationwithstandard-of-carechemotherapies,TL32711hasdemonstratedstrongcorrelationbetweendrugexposure,targetcoverageandapoptosisinductionintumorsatwell-tolerateddosesaswellaspromisinganti-tumoractivityinpatients.TL32711isenteringPhase2singleagentandcombinationclinicalstudiesinsolidtumorsandaPhase1/2clinicalstudyinacutemyeloidleukemia.TetraLogicwillexecuteaPhase2clinicalprogramtoexplorethebroadtherapeuticpotentialofSmacmimeticswiththesupportofsubstantialnon-dilutivefundingthatreducesdownstreamequityrequirements.(source:http://www.tetralogicpharma.com/research_tl32711.html).
References
1:ElsawyMA,TikhonovaIG,MartinSL,WalkerB.Smac-derivedAza-peptideAsanAminopeptidase-resistantXIAPBIR3Antagonist.ProteinPeptLett.2015Jun21.[Epubaheadofprint]PubMedPMID:26095377.
2:EbertG,AllisonC,PrestonS,CooneyJ,ToeJG,StutzMD,OjaimiS,BaschukN,NachburU,TorresiJ,SilkeJ,BegleyCG,PellegriniM.EliminatinghepatitisBbyantagonizingcellularinhibitorsofapoptosis.ProcNatlAcadSciUSA.2015May5;112(18):5803-8.doi:10.1073/pnas.1502400112.Epub2015Apr20.PubMedPMID:25902530;PubMedCentralPMCID:PMC4426438.
3:PapaevangelouE,AlmeidaGS,JaminY,RobinsonSP,deSouzaNM.Diffusion-weightedMRIforimagingcelldeathaftercytotoxicorapoptosis-inducingtherapy.BrJCancer.2015Apr28;112(9):1471-9.doi:10.1038/bjc.2015.134.Epub2015Apr16.PubMedPMID:25880014;PubMedCentralPMCID:PMC4453679.
4:BradySW,ZhangJ,TsaiMH,YuD.PI3K-independentmTORactivationpromoteslapatinibresistanceandIAPexpressionthatcanbeeffectivelyreversedbymTORandHsp90inhibition.CancerBiolTher.2015;16(3):402-11.doi:10.1080/15384047.2014.1002693.PubMedPMID:25692408.
5:LeeEW,SeongD,SeoJ,JeongM,LeeHK,SongJ.USP11-dependentselectivecIAP2deubiquitylationandstABIlizationdeterminesensitivitytoSmacmimetics.CellDeathDiffer.2015Jan23.doi:10.1038/cdd.2014.234.[Epubaheadofprint]PubMedPMID:25613375.
6:EytanDF,SnowGE,CarlsonSG,SchiltzS,ChenZ,VanWaesC.CombinationeffectsofSMACmimeticbirinapantwithTNFα,TRAIL,anddocetaxelinpreclinicalmodelsofHNSCC.Laryngoscope.2015Mar;125(3):E118-24.doi:10.1002/lary.25056.Epub2014Nov28.PubMedPMID:25431358;PubMedCentralPMCID:PMC4336212.
7:MakPY,MakDH,RuvoloV,JacamoR,KornblauSM,KantarjianH,AndreeffM,CarterBZ.Apoptosisrepressorwithcaspaserecruitmentdomainmodulatessecondmitochondrial-derivedactivatorofcaspasesmimetic-inducedcelldeaththroughBIRC2/MAP3K14signallinginacutemyeloidleukaemia.BrJHaematol.2014Nov;167(3):376-84.doi:10.1111/bjh.13054.Epub2014Jul31.PubMedPMID:25079338;PubMedCentralPMCID:PMC4357400.
8:CondonSM,MitsuuchiY,DengY,LaPorteMG,RippinSR,HaimowitzT,AlexanderMD,KumarPT,HendiMS,LeeYH,BenetatosCA,YuG,KapoorGS,NeimanE,SeipelME,BurnsJM,GrahamMA,McKinlayMA,LiX,WangJ,ShiY,FelthamR,BettjemanB,CummingMH,VinceJE,KhanN,SilkeJ,DayCL,ChunduruSK.Birinapant,asmac-mimeticwithimprovedtolerabilityforthetreatmentofsolidtumorsandhematologicalmalignancies.JMedChem.2014May8;57(9):3666-77.doi:10.1021/jm500176w.Epub2014Apr15.PubMedPMID:24684347.
9:BenetatosCA,MitsuuchiY,BurnsJM,NeimanEM,CondonSM,YuG,SeipelME,KapoorGS,LaporteMG,RippinSR,DengY,HendiMS,TirunahariPK,LeeYH,HaimowitzT,AlexanderMD,GrahamMA,WengD,ShiY,McKinlayMA,ChunduruSK.Birinapant(TL32711),abivalentSMACmimetic,targetsTRAF2-associatedcIAPs,abrogatesTNF-inducedNF-κBactivation,andisactiveinpatient-derivedxenograftmodels.MolCancerTher.2014Apr;13(4):867-79.doi:10.1158/1535-7163.MCT-13-0798.Epub2014Feb21.Erratumin:MolCancerTher.2014Sep;13(9):2246-7.Dosageerrorinarticletext.PubMedPMID:24563541.
10:CarterBZ,MakPY,MakDH,ShiY,QiuY,BogenbergerJM,MuH,TibesR,YaoH,CoombesKR,JacamoRO,McQueenT,KornblauSM,AndreeffM.SynergistictargetingofAMLstem/ProgenitorcellswithIAPantagonistbirinapantanddemethylatingagents.JNatlCancerInst.2014Feb;106(2):djt440.doi:10.1093/jnci/djt440.PubMedPMID:24526787;PubMedCentralPMCID:PMC3952202.
